晚期子宫内膜癌按组织学类型分析序贯、同期及三明治辅助治疗的利用与生存结局
基于SEER-Medicare数据库2000至2013年2870例III期子宫内膜癌患者,按组织学类型分析不同辅助治疗模式的总体生存。全部组织学类型中辅助治疗模式与OS相关(log rank P<.05);子宫内膜样癌中三明治模式OS改善最大,浆液性和透明细胞癌中同期放化疗改善最大,癌肉瘤中单纯化疗改善最大。
要点
- 2870例III期子宫内膜癌中31.5%未接受辅助治疗。
- 全部组织学类型中辅助治疗模式与OS相关(log rank P<.05)。
- 子宫内膜样癌三明治模式OS改善最大,浆液性和透明细胞癌同期放化疗改善最大,癌肉瘤单纯化疗改善最大。
核心结论
- 晚期子宫内膜癌的OS因组织学类型和辅助治疗模式不同而存在显著差异。
- 作者建议未来研究应按组织学亚型和分子特征评估联合辅助治疗对比单纯化疗的疗效。
研究设计与样本
- 基于SEER-Medicare数据库识别2000至2013年接受初次手术分期的III期子宫内膜癌患者,共2870例(子宫内膜样癌1798例、浆液性癌606例、透明细胞癌118例、癌肉瘤348例)。
- 辅助治疗按4组比较(无治疗、仅放疗、仅化疗、联合放疗)及8组比较(无治疗、仅放疗、仅化疗、同期放化疗、同期放化疗后化疗、序贯化疗-放疗、序贯放疗-化疗、三明治模式)分组。
- 采用Kaplan-Meier估计、log rank检验和多因素Cox模型分析放疗和化疗模式。
主要发现
- 2870例中31.5%未接受辅助治疗,其余接受单纯放疗或化疗、同期放化疗、序贯或三明治模式。
- 在全部组织学类型合并及按组织学类型分层时,4组和8组比较的校正与未校正模型均显示OS因辅助治疗不同而存在差异(log rank P<.05)。
- 校正分析中,子宫内膜样癌三明治模式OS改善最大,但两两比较未确定哪种以化疗为基础的方案更优。
- 浆液性癌和透明细胞癌中同期放化疗OS改善最大,癌肉瘤中单纯化疗OS改善最大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the impact on overall survival (OS) of different modalities of adjuvant therapy for the treatment of stage III endometrial cancer (EC), by histology. METHODS: Stage 3 endometrioid (EAC), serous (SER), clear cell (CC), and carcinosarcoma (CS) patients who underwent primary surgical staging from 2000 to 2013 were identified in SEER-Medicare. Adjuvant therapy was defined by a 4-arm comparator grouping (none; RT only; CT only; combination RT), as well as by an 8-arm comparator grouping (none; RT only; CT only; concurrent CT-RT; concurrent CT-RT then CT; Serial CT-RT; serial RT-CT; sandwich). Modality of RT and CT were analyzed using Kaplan-Meier estimates, log rank tests, and multivariable cox modeling. RESULTS: Of 2870 cases identified (1798 EAC, 606 SER, 118 CC, 348 CS), 31.5% received no adjuvant therapy. The remainder received RT or CT alone, concurrent RT-CT, serial or sandwich modalities. OS differed by adjuvant therapy in adjusted and unadjusted models, when combining all histologies, and when stratifying by histology using both the 4-arm, and 8-arm comparator analyses (log rank p < .05, all). By histology, in adjusted analyses, sandwich modality had the greatest improvement in OS for endometrioid, but pairwise comparisons did not identify a superior chemotherapy-based regimen. For serous and clear cell, the greatest improvement in OS was seen with concurrent RT-CT, and for carcinosarcoma, CT alone. CONCLUSIONS: OS for advanced EC significantly differs by histology and mode of adjuvant therapy. Future studies should evaluate the efficacy of combination-based adjuvant therapy versus chemotherapy alone, by histologic subtype and molecular signature.
引用
- Ko EM, Brensinger CM, Cory L, et al. Utilization and survival outcomes of sequential, concurrent and sandwich therapies for advanced stage endometrial cancers by histology. Gynecol Oncol. 2020. PMID: 32800655. doi:10.1016/j.ygyno.2020.07.105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。